299 related articles for article (PubMed ID: 18069270)
1. [Biochemical and immunological findings of multiple myeloma].
Asaoku H
Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
[TBL] [Abstract][Full Text] [Related]
2. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
[TBL] [Abstract][Full Text] [Related]
4. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
5. [Prognositic factors in multiple myeloma].
Nagura E
Nihon Rinsho; 2007 Dec; 65(12):2351-6. PubMed ID: 18069282
[TBL] [Abstract][Full Text] [Related]
6. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
9. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
10. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
11. Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias.
Ozsan GH; Dispenzieri A
Expert Rev Clin Immunol; 2011 Jan; 7(1):65-73. PubMed ID: 21162651
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
Vermeersch P; Van Hoovels L; Delforge M; Mariën G; Bossuyt X
Br J Haematol; 2008 Nov; 143(4):496-502. PubMed ID: 18729849
[TBL] [Abstract][Full Text] [Related]
13. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
15. [Serum free light-chain assay for nonsecretory multiple myeloma with light chain cast nephropathy and light chain deposition disease].
Honma R; Fukase S; Suzuki M; Omoto E
Rinsho Ketsueki; 2010 Apr; 51(4):270-4. PubMed ID: 20467224
[TBL] [Abstract][Full Text] [Related]
16. [Classification, staging and prognostic indices for multiple myeloma].
Hotta T
Nihon Rinsho; 2007 Dec; 65(12):2161-6. PubMed ID: 18069256
[TBL] [Abstract][Full Text] [Related]
17. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.
Raja KR; Kovarova L; Hajek R
Br J Haematol; 2010 May; 149(3):334-51. PubMed ID: 20201947
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
Kumar S; Rajkumar SV; Kyle RA; Lacy MQ; Dispenzieri A; Fonseca R; Lust JA; Gertz MA; Greipp PR; Witzig TE
J Clin Oncol; 2005 Aug; 23(24):5668-74. PubMed ID: 16110026
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Petrová P; Minarík J; Pika T; Bacovský J; Adamová D; Langová K;
Klin Onkol; 2010; 23(3):171-81. PubMed ID: 20608327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
